Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cue Biopharma, Inc. is a clinical-stage biotechnology company focused on developing precision immunotherapies designed to selectively modulate disease-relevant T cells. The company operates within the biopharmaceutical and immuno-oncology industries, with a core emphasis on autoimmune diseases, oncology, and immune-mediated disorders. Cue Biopharma’s approach centers on directing immune responses without broad immune activation, positioning it as a differentiated player in targeted immune modulation.
The company’s primary value driver is its proprietary Immuno-STAT™ platform, which is designed to selectively activate or suppress specific T cell populations. Cue Biopharma was founded in 2014 and became a publicly traded company in 2018. Since inception, the company has evolved from a platform-focused research organization into a clinical-stage enterprise advancing multiple therapeutic candidates into human trials, primarily targeting oncology and autoimmune indications.
Business Operations
Cue Biopharma operates as a single operating segment focused on research and development of biologic therapeutics. Revenue generation to date has primarily consisted of collaboration revenue and grant funding, as the company does not yet have approved commercial products. Its lead product candidates are developed using the Immuno-STAT™ platform, which combines peptide-major histocompatibility complexes with modified cytokines to selectively engage specific T cell subsets.
The company conducts its operations mainly in the United States, with research, development, and corporate functions centralized in Massachusetts. Cue Biopharma has entered into strategic collaborations with larger biopharmaceutical companies to support platform validation and development. Public disclosures indicate no material revenue-producing subsidiaries, and operational activities are conducted directly by Cue Biopharma, Inc. Data inconclusive based on available public sources regarding any material joint ventures.
Strategic Position & Investments
Cue Biopharma’s strategic direction is focused on advancing its internal clinical pipeline while leveraging partnerships to expand the applicability of its platform. Growth initiatives prioritize progressing lead oncology and autoimmune programs through early- and mid-stage clinical trials, as well as expanding the Immuno-STAT™ platform into additional disease areas.
The company has engaged in selective collaborations rather than large-scale acquisitions, emphasizing capital efficiency and scientific validation over inorganic growth. Cue Biopharma’s investment focus remains concentrated on immuno-oncology and immune tolerance technologies. Public filings do not indicate ownership of significant portfolio companies or completed acquisitions; any future expansion through acquisitions remains speculative and unverified based on current disclosures.
Geographic Footprint
Cue Biopharma is headquartered in Cambridge, Massachusetts, within the United States, and its core operations are primarily domestic. The company benefits from proximity to a major biotechnology ecosystem, supporting talent acquisition and research collaboration.
International exposure is largely indirect, occurring through clinical trials, academic collaborations, and strategic partnerships that may involve non-U.S. institutions. There is no evidence of material manufacturing or commercial infrastructure outside the United States as of the most recent public disclosures.
Leadership & Governance
Cue Biopharma is led by an executive team with experience in biotechnology, pharmaceuticals, and corporate development. The leadership emphasizes disciplined clinical execution, platform scalability, and strategic partnerships as core elements of its governance philosophy.
Key executives include:
- Daniel R. Passeri – President and Chief Executive Officer
- Patrick J. Mooney – Chief Financial Officer
- Elisabetta Ciaramella, Ph.D. – Chief Scientific Officer
- Kenneth Getz, Ph.D. – Chief Operating Officer
The company is governed by a board of directors with backgrounds spanning biotechnology, finance, and drug development, supporting oversight aligned with long-term shareholder value and scientific rigor.